Your browser doesn't support javascript.
loading
Rheumatic Disease: Protease-Activated Receptor-2 in Synovial Joint Pathobiology.
McCulloch, Kendal; McGrath, Sarah; Huesa, Carmen; Dunning, Lynette; Litherland, Gary; Crilly, Anne; Hultin, Leif; Ferrell, William R; Lockhart, John C; Goodyear, Carl S.
Afiliación
  • McCulloch K; Institute of Biomedical & Environmental Health Research, University of the West of Scotland, Paisley, United Kingdom.
  • McGrath S; Institute of Immunity, Infection & Inflammation, University of Glasgow, Glasgow, United Kingdom.
  • Huesa C; Institute of Biomedical & Environmental Health Research, University of the West of Scotland, Paisley, United Kingdom.
  • Dunning L; Institute of Biomedical & Environmental Health Research, University of the West of Scotland, Paisley, United Kingdom.
  • Litherland G; Institute of Biomedical & Environmental Health Research, University of the West of Scotland, Paisley, United Kingdom.
  • Crilly A; Institute of Biomedical & Environmental Health Research, University of the West of Scotland, Paisley, United Kingdom.
  • Hultin L; Respiratory, Inflammation and Autoimmunity, Innovative Medicines and Early Development, AstraZeneca, Mölndal, Sweden.
  • Ferrell WR; Institute of Immunity, Infection & Inflammation, University of Glasgow, Glasgow, United Kingdom.
  • Lockhart JC; Institute of Biomedical & Environmental Health Research, University of the West of Scotland, Paisley, United Kingdom.
  • Goodyear CS; Institute of Immunity, Infection & Inflammation, University of Glasgow, Glasgow, United Kingdom.
Article en En | MEDLINE | ID: mdl-29875735
ABSTRACT
Protease-activated receptor-2 (PAR2) is one member of a small family of transmembrane, G-protein-coupled receptors. These receptors are activated via cleavage of their N terminus by serine proteases (e.g., tryptase), unveiling an N terminus tethered ligand which binds to the second extracellular loop of the receptor. Increasing evidence has emerged identifying key pathophysiological roles for PAR2 in both rheumatoid arthritis (RA) and osteoarthritis (OA). Importantly, this includes both pro-inflammatory and destructive roles. For example, in murine models of RA, the associated synovitis, cartilage degradation, and subsequent bone erosion are all significantly reduced in the absence of PAR2. Similarly, in experimental models of OA, PAR2 disruption confers protection against cartilage degradation, subchondral bone osteosclerosis, and osteophyte formation. This review focuses on the role of PAR2 in rheumatic disease and its potential as an important therapeutic target for treating pain and joint degradation.
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Idioma: En Revista: Front Endocrinol (Lausanne) Año: 2018 Tipo del documento: Article País de afiliación: Reino Unido

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Idioma: En Revista: Front Endocrinol (Lausanne) Año: 2018 Tipo del documento: Article País de afiliación: Reino Unido